appe mi		Sheet 1 of 1
Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce	ATTORNEY DOCKET NO.	601-1-077DIV1
Patent and Trademark Office	SERIAL NO.	10/643,233
LIST OF DOCUMENTARY INFORMATION	APPLICANT	Peter Lobel, et al.
CITED BY APPLICANT (Supplemental Information Disclosure Statement)	FILING DATE	August 18, 2003

GROUP 1632

## **U.S. PATENT DOCUMENTS**

EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
				-		

## FOREIGN PATENT DOCUMENTS

 DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
***************************************					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AS	АН	B. L. Davidson, et al., Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system, P. Natl. Acad. Sci., 97:3428-3432 (2000)					
	Al	X. Xiao, et al., Gene transfer by adeno-asso system, Exp. Neurol, 144:113-24 (1997) Abs		e central nervous			
	AJ.	K.R. Clark, et al., Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression, J Drug Target, 7:269-83 (19 Abstract					
	AK	M.A. Passini, et al., Intracranial delivery of C classical late infantile neuronal ceroid lipofu 1342 (2006)					
	AL	D. Sondhi, et al., AAV2-mediated CLN2 gen results in long-term TPP-1 expression comp 12:1618-1632 (2005)					
V	АМ	R.E. Haskell, et al., Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-1 to the mouse central nervous system, Gene Therapy, 10:34-42 (2003)					
AS	AS  N.R. Hackett, et al., Safety of direct administration of AAV2 <sub>cu</sub> hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates, Human Gene Therapy, 16:1484-1503 (2005)						
EXAMINE	₹:	/Anoop Singh/	DATE CONSIDERED:	10/12/2006			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.